His research interests are in the use of novel imaging for evaluation of prognosis, the assessment of responses to therapy and as an early indicator of inflammation suppression as well as disease modification particularly as applied to early phase clinical trial design. He has recently pioneered studies using such measures as primary outcome measures in early phase Ib/IIa studies with a view to informing later phase study design. He has been a principal investigator in numerous international clinical trials of biologic therapies including the earliest seminal trails of anti-TNF and anti-IL-6 receptor therapy and is currently chief investigator in a number of small molecule therapies in clinical trials for rheumatoid arthritis and ankylosing spondylitis.